Cytokinetics, Incorporated (CYTK)

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization in the European Union (EU) for MYQORZO® (aficamten), a cardiac myosin inhibitor, for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.

Added 458,295 shares of Cytokinetics, a $25,187,893 net position change Transaction represents a 13.8% position relative to 13F reportable assets under management Post-trade stake: 458,295 shares valued at $25,187,893 CYTK is now the fund's 2nd-largest holding by reported U.S. equity positions These 10 Stocks Could Mint the Next Wave of Millionaires ›

Cytokinetics, Incorporated (NASDAQ: CYTK - Get Free Report) EVP Andrew Callos sold 52,486 shares of the stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $65.95, for a total transaction of $3,461,451.70. Following the completion of the transaction, the executive vice president directly owned 50,660 shares in the

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?

Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) by 8.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 30,684 shares of the biopharmaceutical company's stock after buying an additional 2,474 shares during

Cytokinetics is positioned as a precision cardiac mechanics platform leader, with aficamten as the first proof-of-concept and multiple pipeline assets. Aficamten's differentiated REMS, rapid titration, and superior safety could disrupt the cardiac myosin inhibitor market, expanding prescriber adoption and accelerating patient switching from competitors. CYTK's robust cash position, efficient commercial model, and underappreciated pipeline support a sum-of-the-parts valuation of $90–$158 per share, far above current levels.

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to Jeffrey Hessekiel, the Company's Executive Vice President, Chief Legal and Administrative Officer, whose employment commenced on November 14, 2025, as a material inducement to his employment.

NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period"), of the important November 17, 2025 lead plaintiff deadline. So what: If you purchased Cytokinetics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

New York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ: CYTK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-form-2?prid=177791&wire=5&utm_campaign=7 or contact Joseph E. Levi, Esq.

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit.

New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period"), of the important November 17, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cytokinetics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK--(BUSINESS WIRE)---- $CYTK #CYTK--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) and reminds investors of the November 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Ge.

LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 17, 2025.

LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Incorporated, (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of investors that bought securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion.

NEW YORK , Nov. 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

System of Care to Advance Care for the Most Commonly Inherited Heart Disease SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) --  Cytokinetics, Inc. (Nasdaq: CYTK) today announced its support of a three-year initiative led by the American Heart Association to address disparities in access to care, diagnosis, and treatment for people living with hypertrophic cardiomyopathy (HCM), a chronic and often underdiagnosed heart disease that affects hundreds of thousands of individuals across the United States.